Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ: SRRK) has successfully closed a $50 million debt facility with Silicon Valley Bank and Oxford Finance LLC, with an initial funding of $25 million. The funding aims to support general corporate purposes, including advancing their clinical pipeline and pre-commercialization preparations. The second tranche of $25 million is accessible upon certain clinical milestones. This financing is intended to enhance Scholar Rock's financial flexibility as it approaches significant clinical read-outs for its product candidates targeting serious diseases, such as SRK-015 and SRK-181.
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company, announced two poster presentations at the World Muscle Society 2020 Virtual Congress. The posters will cover clinical development data for SRK-015, an investigational therapy for Type 2 and Type 3 Spinal Muscular Atrophy (SMA), detailing findings from a Phase 1 trial and the ongoing Phase 2 TOPAZ trial. The TOPAZ trial is fully enrolled, with an interim analysis expected in Q4 2020. SRK-015 has received Orphan Drug and Rare Pediatric Disease designations, though its safety and efficacy remain unestablished.